Navigation Links
CryoLife to Present at Upcoming Investor Conferences in New York
Date:11/11/2009

ATLANTA, Nov. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present in the upcoming Lazard Capital Markets Sixth Annual Healthcare Conference on Wednesday, November 18, 2009 at 1:15 pm ET in New York City. CryoLife's live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.

CryoLife is also scheduled to present at the Sidoti & Company Emerging Growth Institutional Investor Forum on November 20, 2009. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer will present at 9:40 am ET in New York City.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The Company's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch. The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial Officer and
    Chief Operating Officer
    Phone: 770-419-3355

SOURCE CryoLife, Inc.


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues of $28.2 Million
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
4. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
5. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
6. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
7. VIVUS to Present at Lazard Capital Markets Healthcare Conference
8. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
9. Thoratec Presentation at Canaccord Adams Conference to be Webcast
10. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
11. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
(Date:2/23/2017)... ... Markets has announced the addition of the "Global Antifungal Drugs Market ... offering. The Global Antifungal Drugs Market is poised to ... reach approximately $12.8 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/23/2017)... 2017 Persistence Market Research ... market for intraoperative imaging, excerpts from which predict ... 513.9 million. According to the report, the demand ... grounds of increasing adoption of minimally-invasive surgeries and ... imaging for neurosurgeries. The world,s leading medical research ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company that focuses on ... are coming soon to Amazon.com, the world’s largest online retailer. , The ... develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® ... of individuals who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent ... California, where they are free from the shame, stigma, and harmful labeling ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National ... requirements effective with the April 2017 testing period. NACCM, a nonprofit organization, has ... Manager Certified (CMC) exam is periodically re-calibrated to ensure that newly certified professionals ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients ... trips the emergency room, fewer hospital admissions, and better blood pressure and glycemic ... (AJMC®) finds. The study can be found here . , The study ...
Breaking Medicine News(10 mins):